There is a clinically unmet need for effective treatments for triple-negative breast cancer
(TNBC), as it remains the most aggressive subtype of breast cancer. Herein, we demonstrate …

We characterize the in vivo biodistribution and tumor selectivity of 86Y-NM600, a theranostic
alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of …

Purpose Pathological complete response to the neoadjuvant therapy (NAT) for triple
negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early …

Purpose Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast
cancer that lacks effective diagnostic and therapeutic options. Membrane type 1 matrix …

Currently, most patients with non–small cell lung cancer (NSCLC) are diagnosed in
advanced stages with a poor five-year survival rate. Therefore, intensive research aimed at …

Triple-negative breast cancer (TNBC) has a high risk for recurrence and metastasis. We
studied the effectiveness of Auger electron (AE) radioimmunotherapy (RIT) with …

Background Triple-negative breast cancer (TNBC) represents an aggressive subtype with
limited therapeutic options. Experimental preclinical models that recapitulate their tumors of …

Triple-negative breast cancer (TNBC) is associated with poor survival. Chemotherapy is the
only standard treatment for TNBC. The prevalence of BRCA1 inactivation in TNBC has …

Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer and
disproportionately accounts for the majority of breast cancer related deaths. Effective …

The current standard for breast PET imaging is 18F-FDG. The heterogeneity of 18F-FDG
uptake in breast cancer limits its utility, varying greatly among receptor status …